• 1
    Woosley RL, Sale M. QT interval. A measure of drug action. Am J Cardiol 1993; 72: 36B43B.
  • 2
    De Abajo FJ, Rodriguez LA. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol 1999; 47: 307313.
  • 3
    De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000; 56: 118.
  • 4
    Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol 2000; 83: 119.
  • 5
    Sheridan DJ. Drug-induced proarrhythmic effects. Assessment of changes in QT interval. Br J Clin Pharmacol 2000; 50: 297302.
  • 6
    De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57: 185209.
  • 7
    WHO. Collaborating Centre for Drug Statistics Methodology (Norway, 1999 ATC index with DDDs, Oslo, Norway): the WHO Collaborating Centre.
  • 8
    McManus P, Mant A, Mitchell PB, Montgomery WS, Marley J, Auland ME. Recent trends in the use of antidepressant drugs in Australia, 1990–1998. Med J Aust 2000; 173: 458461.
  • 9
    Janson C, Chinn S, Jarvis D, Burney P. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J 1997; 10: 17951802.
  • 10
    Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001; 24: 323351.
  • 11
    European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP): Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products 1997.
  • 12
    Ikeda T. QT prolongation in type 2 diabetes mellitus treated with glibenclamide. Diabetes Metab 1994; 20: 565567.
  • 13
    Rosati B, Rocchetti M, Zaza A, Wanke E. Sulfonylureas blockade of neural and cardiac HERG channels. FEBS Lett 1998; 440: 125130.
  • 14
    Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000; 21: 220229.
  • 15
    Pinto YM, Van Gelder IC, Heeringa M, Crijns HJGM. QT lengthening and life-threatening arrhytmias associated with fexofenadine. Lancet 1999; 353: 980.
  • 16
    Dhar S, Hazra PK, Malakar S, Mistri G. Fexofenadine-induced QT prolongation: a myth or fact? Br J Dermatol 2000; 142: 12601261.
  • 17
    Craig-McFeely PM, Freemantle SL, Pearce GL, Shakir SA. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Br J General Pract 2000; 50: 148.
  • 18
    Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 2002; 300: 543548.
  • 19
    Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21: 5256.
  • 20
    Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001; 52: 201204.
  • 21
    Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001; 12: 411420.
  • 22
    Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moye L. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994; 73: 346352.
  • 23
    Hanrahan JP, Choo PW, Carlson W, Greineder D, Faich GA, Platt R. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 1995; 5: 201209.